Manufacturer
Amgen Biopharmaceuticals Malaysia Sdn Bhd
Contents
Blinatumomab
Indication
Minimal residual disease (MRD) positive, relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Drug interaction
Monitor for toxicity (eg, warfarin) or drug conc (eg, cyclosporine) w/ CYP450 substrates.
Amgen Biopharmaceuticals Malaysia Sdn Bhd
Contents
Blinatumomab
Indication
Minimal residual disease (MRD) positive, relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Drug interaction
Monitor for toxicity (eg, warfarin) or drug conc (eg, cyclosporine) w/ CYP450 substrates.
Inquiry - BLINCYTO (Blinatumomab) for injection 35 mcg/vial